Share chart Kodiak Sciences Inc.
Extended chart
Simple chart
About
Kodiak Sciences Inc., биофармацевтическая компания, работающая на клинической стадии, предлагает новые терапевтические препараты для лечения заболеваний сетчатки. Ведущим кандидатом на продукт компании является KSI-301, биологический агент фактора роста эндотелия сосудов (VEGF), который находится в фазе 1b клинического исследования для лечения влажной возрастной дегенерации желтого пятна (AMD) и диабетической ретинопатии.
More details| P/BV | 7.42 |
|---|---|
| EV/EBITDA | -49.66 |
| EBITDA | -0.0474 |
| Цена ао | 3.61 |
| Сайт | http://kodiak.com |
| Число акций ао | 0.05241 млрд |
| Див.доход ао | 0 |
| ISIN | US50015M1099 |
| P/E | 0.001 |
| Валюта | usd |
| IPO date | 2018-10-04 |
| Sector | Health Care |
| Industry | Biotechnology |
| Валюта отчета | usd |
| Change price per day: | +5.58% (2.69) |
|---|---|
| Change price per week: | +6.77% (2.66) |
| Change price per month: | +19.33% (2.38) |
| Change price per 3 month: | -4.05% (2.96) |
| Change price per half year: | -26.99% (3.89) |
| Change price per year: | +71.08% (1.66) |
| Change price per 3 year: | -97.46% (111.63) |
| Change price per 5 year: | -84.4% (18.2) |
| Change price per year to date: | +16.87% (2.43) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Baker Brothers Advisors, LLC | 17310490 | 32.97 |
| Blackrock Inc. | 4032822 | 7.68 |
| Acadian Asset Management. LLC | 1908302 | 3.63 |
| Newtyn Management, LLC | 1771241 | 3.37 |
| Vanguard Group Inc | 1643470 | 3.13 |
| Shaw D.E. & Co., Inc. | 1208973 | 2.3 |
| ICONIQ Capital, LLC | 1016864 | 1.94 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1000000 | 1.9 |
| Jacobs Levy Equity Management, Inc. | 723675 | 1.38 |
| State Street Corporation | 720435 | 1.37 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Avantis U.S Small Cap Equity ETF | 0.01021 | 27.774101036841 | 1.68271 |
| Avantis U.S. Equity ETF | 0.00012 | 30.365392144069 | 1.59151 |
| ProShares UltraShort Nasdaq Biotechnology | 0.35 | -40.363937138131 | 1.76 |
| Dimensional U.S. Targeted Value ETF | 0.00235 | 26.007247921552 | 1.93487 |
| Dimensional US Core Equity Market ETF | 0.00007 | 30.983243755928 | 1.40618 |
| Dimensional U.S. Equity ETF | 0.00006 | 31.530984204131 | 1.3557 |
| ProShares Hedge Replication ETF | 0.00053 | 5.9237999659878 | 1.47892 |
| iShares Micro-Cap ETF | 0.02184 | 34.327031588619 | 1.54048 |
| iShares Russell 3000 ETF | 0.00025 | 31.230028873917 | 1.43482 |
| Invesco FTSE RAFI US 1500 Small-Mid ETF | 0.00536 | 32.025164769323 | 1.75869 |
| Schwab U.S. Small-Cap ETF | 0.00234 | -34.641922436355 | 1.51433 |
| Schwab U.S. Broad Market ETF | 0.00018 | -56.193181818182 | 1.43354 |
| ProShares UltraPro Russell2000 | 0.00186 | 89.821266282945 | 1.47873 |
| Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
| Vanguard Russell 2000 ETF | 0 | 32.773459189339 | 1.48801 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Ms. Almas Qudrat M.Sc. | Chief Quality Officer | N/A | |
| Dr. Victor Perlroth M.D. | Co-Founder, Chairman, CEO & President | 1.08M | 1973 (51 year) |
| Dr. Stephen Raillard Ph.D. | Senior Vice President of Chemical Development & Manufacturing | N/A | |
| Dr. J. Pablo Velazquez-Martin M.D. | Chief Medical Officer | N/A | |
| Mr. John A. Borgeson CPA, M.B.A. | Executive VP, CFO & Secretary | 667.52k | 1963 (61 year) |
| Dr. Dolly S. Chang M.D., M.P.H., Ph.D. | Chief Scientific Officer | ||
| Dr. Hong Liang Ph.D. | Senior Vice President of Development | 1972 (52 years) | |
| Ms. Tracy Chien | VP & Corporate Controller |
Address: United States, Palo Alto, CA , 1200 Page Mill Road - open in Google maps, open in Yandex maps
Website: http://kodiak.com
Website: http://kodiak.com
